BLOG

AI tools that answer questions are not enough. Learn how Sitero's Ash AI delivers governed, audit-ready workflows for data management, study configuration, and insights.

Cell and gene therapy trials are scaling faster than biosafety infrastructure. Learn why IBC requirements, NIH Guidelines, and site activation challenges are delaying CGT programs, and how Sitero’s biosafety team helps sponsors stay ahead.

Clinical Operations Visibility Framework by Sitero

Evaluating a CRO for a biomarker-driven oncology trial? Use these questions on site selection, central lab coordination, EDC design, and screening failure management.

In an adaptive oncology trial, the RTSM must do four things that a conventional randomization system is not required to do: enforce configurable cohort and dose assignment rules in real [...]

Central lab workflow design determines enrollment velocity in precision oncology. Learn how to structure turnaround SLAs, result notification, and re-biopsy processes.

Biomarker-driven oncology trials enroll slowly because eligibility depends on a chain of steps — tissue procurement, sample shipment, lab processing, result communication, and site decision — each owned by a [...]

Adaptive oncology trials fail operationally, not statistically. Learn what data readiness, RTSM configuration, and DSMB preparation actually require in execution.

Drug supply management in an umbrella trial requires RTSM configuration that explicitly models arm expansion and arm closure scenarios — not supply planning for the initial design with manual adjustments [...]

Data readiness for adaptive trial interim analysis is an operational problem solved months before the window arrives. Here's what must be true before your DSMB can decide.

Running a basket trial operationally requires infrastructure that treats each tumor type cohort as a distinct operational unit within a shared governance framework: cohort-specific site selection (not study-level), a central [...]

A well-governed basket or umbrella trial requires four explicitly designed governance bodies: a Steering Committee with defined decision authority over major protocol changes, an IDMC chartered specifically for adaptive review [...]